Find a Clinical Trial

Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn 1) if gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated and 2) if people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away.

The goals of this study are to learn 1) about the safety of combining gocatamig and I-DXd and if people tolerate them together and 2) if people who receive gocatamig and I-DXd have ES-SCLC respond, which means the cancer gets smaller or goes away.

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).

The study will address the hypothesis that telisotuzumab adizutecan in combination with a PD-1 immune check point inhibitor (budigalimab or pembrolizumab) can be safely administered and telisotuzumab adizutecan in combination with pembrolizumab will provide a favorable risk/benefit profile compared to the SOC control (pembrolizumab and platinum doublet) in subjects with locally advanced/metastatic NSq NSCLC who have no prior systemic therapy for advanced disease and who are EGFR WT and have no known other actionable genomic alterations.

The current study will test the feasibility of using an engineering-inspired study design to identify effective COPD self-management treatment components.

The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 subjects with KRASG12C mutant NSCLC that have not been exposed to prior therapy with KRASG12C inhibitors and/or SHP2 inhibitors.

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC).